Most prior work with positron emission tomography (PET) dopamine subtype 2/3 receptor (D 2/3 R) non-selective antagonist tracers suggests that obese (OB) individuals exhibit lower D 2/3 Rs when compared with normal weight (NW) individuals. A D 3 -preferring D 2/3 R agonist tracer, [
INTRODUCTION
It has been estimated that over one-third of Americans are obese (OB) (Flegal et al, 2012) and thus at increased risk for developing obesity-related comorbidities such as coronary artery disease, hypertension, functional limitations, and type-2 diabetes (Field et al, 2001; Lakdawalla et al, 2004; Mokdad et al, 2003; Must et al, 1999; Sturm et al, 2004) . Considerable preclinical and human research examining obesity has focused on dopamine 2/3 receptors (D 2/3 Rs) due to their expression within brain regions associated with reward and motivation such as the striatum and the substantia nigra/ventral tegmental area (SN/VTA). In rodents, D 2 R density was lower in the dorsal striatum of chronic high-fatinduced OB mice as compared with OB-resistant and low-fat-fed controls (Huang et al, 2006) , implicating lower D 2 R availability similar to rodent stimulant administration paradigms (Culver et al, 2008; Dalley et al, 2007; Ujike et al, 1989; Yi and Johnson, 1990) . Further work has investigated a selective D 3 -antagonist medication in an operant food self-administration paradigm and showed that a D 3 -antagonist attenuated lever presses and food intake in both lean and OB rats, providing preliminary evidence of D 3 R-related motivation to consume food (Thanos et al, 2008) . This notion is consistent with clinical data implicating the D 3 R in populations abusing substances that influence nigrostriatal reward pathway function (Boileau et al, 2012; Erritzoe et al, 2014; Matuskey et al, 2014; Payer et al, 2014) .
In humans, prior work utilizing positron emission tomography (PET) and D 2/3 R antagonist tracers has not yielded particularly well-defined results in obesity (for a comprehensive review of the PET dopaminergic and obesity/ BMI literature, please see the work of Val-Laillet et al (2015) . Studies employing [ 11 C]raclopride, a D 2/3 R non-selective tracer, have demonstrated lower striatal D 2/3 R availability in both severely obese (body mass index (BMI)439.9 kg/m 2 ) and OB kg/m 2 ) individuals (Haltia et al, 2007) when compared with normal-weight (NW) .9 kg/m 2 ) individuals. Furthermore, within both severely obese and OB (Haltia et al, 2007) individuals, a negative linear association between D 2/3 R availability and BMI was observed. This relationship did not extend to non-OB individuals, where no associations between striatal D 2/3 R availability and BMI have been found with [ 11 C]raclopride (Caravaggio et al, 2013) . Work done with the D 2 -high affinity tracer, [ 11 C]N-methyl-benperidol (NMB), failed to show any striatal D 2/3 R availability alterations between NW and severely obese individuals (Eisenstein et al, 2013 (Guo et al, 2014) . The D 3 -preferring D 2/3 R agonist PET tracer, [
11 C](+) PHNO, has been found to be especially reliable (due to an excellent specific-to-nonspecific binding ratio) at quantifying extrastriatal midbrain reward regions particularly essential for the synthesis and production of dopamine such as the SN/VTA, where D 3 Rs are predominant (Graff-Guerrero et al, 2008; Narendran et al, 2006; Searle et al, 2010; Tziortzi et al, 2011) . In addition, [
11 C](+)PHNO has also been shown to bind to high-affinity, presumably 'active', G-protein coupled forms of the D 2 R within the striatum (Shotbolt et al, 2012; Willeit et al, 2006) . Prior work done with [ 11 C](+) PHNO has indicated that BMI correlated positively with D 2/3 R availability in the ventral striatum (VST) (Caravaggio et al, 2013) , a region of mixed D 2 Rs and D 3 Rs (Tziortzi et al, 2011) , in a cohort with a relatively narrow non-OB BMI range (range 18.6-27.8 kg/m 2 , mean 23.4 kg/m 2 ). Further work in a wide-BMI-ranged (range 21.5-36.5 kg/m 2 , mean 27.9 kg/m 2 ) small cohort showed a positive association between D 2/3 R availability and BMI in the right dorsal caudate (Cosgrove et al, 2015) .
The current study investigated, for the first time, differences in D 2/3 R availability between 14 OB and 14 ageand gender-matched NW individuals utilizing [ 11 C](+) PHNO PET. Additionally, in regions where D 2/3 R differences were observed, a cohort of 14 overweight (OW) individuals was added to investigate linear associations in a sample representative of the United States population based on BMI (ie,~33% NW,~33% OW, and~33% OB) (Flegal et al, 2012) . Based on prior work (Caravaggio et al, 2013) and tracer-binding characteristics (Shotbolt et al, 2012; Tziortzi et al, 2011) , we expected to observe higher [ 11 C](+)PHNO tracer binding in important brain reward areas in OB compared with NW individuals in regions populated with D 3 Rs (ie, the SN/VTA) and in mixed striatal regions where high-affinity 'active' forms of the D 2 R may exist (ie, VST) as well as positive linear relationships between tracer binding and BMI in those respective regions after the OW cohort was added. Overall, this work aims to extend the obesity literature by providing useful and informative data contributing to mechanistic understanding of the disease and identify potential novel pharmacologic targets for treatment.
MATERIALS AND METHODS
Research participants were recruited from the greater New Haven area by advertisement, word of mouth, and referral. Once determined initially eligible through telephone questionnaire, participants reported to the Yale PET Center or the Clinical Neuroscience Research Unit of the Connecticut Mental Health Center where they were consented and screened by members of the research team. As part of the screening process, study participants underwent comprehensive medical and psychiatric histories, physical examination, neurological and mental status exam, routine laboratory studies, electrocardiogram, and a semistructured (Sheehan et al, 1998) or a structured clinical interview (American Psychiatric Association. and American Psychiatric Association. Task Force on DSM-IV, 2000) to confirm study eligibility. Study participants were excluded based on evidence of a current or previous major psychiatric (eg, schizophrenia or bipolar disorder) or eating disorder (eg, binge eating disorder), current or history of serious medical or neurological illness (eg, past traumatic brain injury resulting in loss of consciousness), current pregnancy (as documented by urine human chorionic gonadotropin testing at screening and on the day of PET imaging), current or history of a substance abuse disorder, evidence of drug use on day of screening and day of imaging (as documented by urine toxicology studies), taking weight loss medications or medications known to influence the dopamine system (eg, methylphenidate or amphetamine), breastfeeding, or contraindications to magnetic resonance imaging.
Fourteen otherwise healthy OB (BMI429.9 kg/m 2 ) individuals were compared with 14 age-and gender-matched healthy NW (BMI 18.5-24.9 kg/m 2 ) individuals. As part of the secondary analyses, 14 otherwise healthy OW (BMI 25-29.9 kg/m 2 ) individuals were added to the analysis to examine the linear association between BMI and D 2/3 R availability in a large, broad-BMI-ranged cohort (see Tables 1  and 2 for means and standard deviations of demographics, injection parameters, and radioactivity data for all individuals studied). All participants with the exception of one D 2/3 R alterations in obesity EC Gaiser et al OW participant were non-nicotine/tobacco users and some have been reported on elsewhere (Matuskey et al, 2015; Matuskey et al, 2016) . Once research participants were eligible for the study, they were asked to abstain from all food and liquids (except for water) the night prior to presenting to the Yale PET Center for imaging until the scanning procedures were completed. [
11 C](+)PHNO was prepared as previously reported (Gallezot et al, 2012) . All PET scans were performed with the high-resolution research tomograph (Siemens/CTI, Knoxville, TN, USA), which acquired 207 slices separated by 1.2 mm with a reconstructed image resolution of~3 mm. Scans were acquired over 120 min at rest. Prior to [ 11 C](+) PHNO emission imaging, a transmission scan was obtained for attenuation correction.
Motion correction was based on an optical detector (Vicra; NDI Systems, Waterloo, Ontario, Canada). Dynamic PET imaging data were reconstructed with corrections for attenuation, normalization, scatter, randoms, deadtime, and motion employing the MOLAR algorithm (Carson et al, 2003) with a frame timing of 6 × 30 s; 3 × 1 min; 2 × 2 min; and 22 × 5 min.
PET data were used to construct a time-activity curve for the cerebellum, a region of minimal D 2/3 R binding, which was used as the reference region as in previous studies (Boileau et al, 2012; Ginovart et al, 2007; Matuskey et al, 2014 Matuskey et al, , 2015 Matuskey et al, , 2016 Mizrahi et al, 2011; Payer et al, 2014; Searle et al, 2010) . A summed image (0-10 min after injection) was created from the motion-corrected PET data and registered to the participant's MR image, which was nonlinearly registered to an MR template in Montreal Neurological Institute (MNI) space. All transformations were performed with Bioimagesuite (version 2.5; http://www.bioimagesuite. com). Parametric images of non-displaceable tracer binding potentials (BP ND ), which are linearly proportional to the density of available D 2/3 Rs, were computed using a simplified reference tissue model (2-parameter version: SRTM2). This method has been previously validated for [ 11 C](+)PHNO (Gallezot et al, 2014b; Wu and Carson, 2002) and utilized to optimize the statistical quality of the SRTM applied in prior studies by reducing noise of the functional images (Matuskey et al, 2014 (Matuskey et al, , 2015 . Unbound concentration in tissue was estimated as the radioligand mass concentration in the cerebellum at 60-90 min post injection.
Structural magnetic resonance imaging (MRI) was performed on a 3-Tesla Trio system (Siemens Medical Solutions, Malvern, Pennsylvania) with a circularly polarized head coil for reasons of excluding individuals with anatomical abnormalities and anatomically coregistering with PET images. The dimension and voxel size of MR images were 256 × 256 × 176 voxels and 0.98 × 0.98 × 1.0 mm 3 , respectively.
Regions of interest (ROIs) included the amygdala, caudate, hypothalamus, pallidum, putamen, SN/VTA, thalamus, and VST. ROIs were based on the automated anatomical labeling template delineated in MNI space (Tzourio-Mazoyer et al, 2002) , with the exception of the hypothalamus, SN/VTA, and VST. More specifically, the hypothalamus was manually delineated on the MRI template image, the template SN/VTA ROI was manually delineated using [
11 C](+)PHNO BP ND images from a previous study (Gallezot et al, 2014b) , and individual, hand-drawn VST delineations were performed in MNI space on each subject's MRI based on the guidelines described by Mawlawi et al (2001) . ROIs were applied to the parametric BP ND images to extract individual values.
In addition to ROI analyses, a voxel-wise analysis was performed on parametric BP ND images with SPM12 (Wellcome Trust Centre for Neuroimaging, London, UK). Similar to the ROI methods, summed PET images were registered to participants' MR images before optimized unified segmentation (Ashburner and Friston, 2005 ) was used to determine nonlinear registrations into MNI standard space. Transformations were applied to parametric BP ND images, resliced into 2 × 2 × 2 mm isotropic voxels and smoothed using a 2-mm FWHM Gaussian kernel. Group differences were assessed using a two-sample t-test at a voxel-level threshold of po0.001 with a cluster extent threshold (k)410 voxels.
Data were summarized descriptively and assessed for normality prior to analyses employing normality probability plots and Kolmogorov test statistics. Linear mixed models were used to examine the independent and joint effects of obesity (between-group factor) and ROIs (within-group) on BP ND values. Between-group differences within each region were estimated to explain significant interactions. Withingroup associations were accounted for by fitting three variance-covariance structures to the data (unstructured, compound symmetry, and heterogeneous compound symmetry) with an unstructured form fitting the data best according to the Bayesian Information Criterion. Secondary correlation analyses were not adjusted for multiple tests given the targeted nature of the analyses (ie, based on the betweengroup findings). All analyses were conducted using SAS version 9.3 (Cary, NC) or SPSS version 22 (Armonk, NY) and considered significant at the two-tailed α = 0.05 threshold.
RESULTS
We observed a main effect of obesity (F 1,26 = 6.11, p = 0.020) demonstrating that OB and NW individuals differed in overall D 2/3 R availability as well as a group-by-brain region interaction effect (F 7,182 = 2.08, p = 0.047) between OB and NW individuals. Post hoc analyses revealed that OB participants exhibited higher D 2/3 R availability compared with NW individuals in the SN/VTA (+20%; F 1,182 = 5.13, p = 0.025), the VST (+14%; F ,182 = 8.14, p = 0.005), and the pallidum (+11%; F 1,182 = 5.30, p = 0.022). Group-by-brain interaction results persisted after independently adjusting for potential confounding effects of age (F 7,182 = 2.06, p = 0.050), gender (F 7,182 = 2.08, p = 0.048), specific activity at time of injection (F 7,182 = 2.08, p = 0.048), and injected mass (F 7,182 = 2.07, p = 0.048). Post hoc results were unaffected by these confounding variables similar to the unadjusted models. Further, there were no differences observed between groups in mean cerebellar mass concentration of unbound [ 11 C](+)PHNO, thus providing additional evidence that these results were not driven by injected mass. Of the three regional findings, the VST was the only brain region that survived correction for multiple comparisons utilizing the Bonferroni method (adjusted α threshold = 0.05/8 = 0.006). Mean BP ND values for both OB and NW individuals along with relative group differences are shown in Table 3 . Voxelwise analyses confirmed significant ROI findings of higher D 2/3 R availability in OB as compared with NW individuals in the SN/VTA, VST, and pallidum (Table 4 and Figure 1) .
The secondary analyses employing a larger cohort to include OW individuals in the above-mentioned significant regions indicated that BMI was positively associated with D 2/3 R availability in the SN/VTA (r = 0.34, p = 0.029; Figure 2a ), the VST (r = 0.36, p = 0.018; Figure 2b) , and the pallidum (r = 0.30, p = 0.051; Figure 2c ) across all subjects. Although these regions were targeted based on our betweengroup comparisons, none of these associations survived correction for multiple comparisons using Bonferroni correction (adjusted α threshold = 0.05/3 = 0.017). That stated, the associations persisted after independently adjusting for age (SN/VTA: r = 0.32, p = 0.043; VST: r = 0.37, p = 0.018; pallidum: r = 0.31, p = 0. 
DISCUSSION
To the best of our knowledge, the current study is the first to utilize the D 3 -preferring D 2/3 R agonist tracer [ 11 C](+)PHNO to assess both striatal and extrastriatal D 2/3 R availability differences between otherwise healthy OB and age-and gender-matched NW individuals. Specifically, this work demonstrated that OB individuals exhibited higher D 2/3 Rs in both extrastriatal (ie, SN/VTA and pallidum) and striatal (ie, VST) regions associated with reward and motivation with the latter finding being the first published difference in any addiction-like condition with [ 11 C](+)PHNO in the striatum. These results were unaffected by adjustment for potential confounding factors such as age (Ishibashi et al, 2009; Kim et al, 2011; Matuskey et al, 2016; Nakajima et al, 2015; Volkow et al, 2000) or tracer injection parameters, and were confirmed with a whole-brain voxel-wise analysis. Moreover, after adding a cohort of OW individuals, we observed a positive linear association between BMI and D 2/3 R availability in the aforementioned regions that also persisted after adjusting for age, gender, and tracer injection parameters.
Prior work with [ 11 C](+)PHNO has demonstrated in non-OB individuals a positive linear association between BMI and tracer binding in the VST (Caravaggio et al, 2013) . Our work extends those findings into an OB population when BMI categorical cohorts were combined. Other work with [ 11 C] (+)PHNO has also yielded a positive linear association (Cosgrove et al, 2015) . The small cohort studied, as well as the unilateral nature of the finding in the dorsal caudate, warrants caution however. Additionally, the current work, one that includes the largest cohort to date examining D 2/3 R alterations imaged with [ 11 C](+)PHNO as related to BMI, did not observe any receptor differences between OB and NW individuals in the dorsal striatum.
Much prior PET and obesity research has utilized D 2/3 R antagonist tracers. Like our current work, studies that used [
18 F]fallypride have demonstrated positive associations between BMI and striatal D 2/3 R availability (although in the dorsal and not the VST) in a large, wide-BMI-ranged cohort (Guo et al, 2014) as well as non-statistically significant higher tracer binding in the SN/VTA of OB as compared with NW females (Savage et al, 2014) . That stated, our work is not consistent with studies that used other D 2/3 R antagonist tracers. For instance, work with [ 11 C]raclopride has demonstrated reductions in striatal D 2/3 R availability in both severely obese ) and OB (Haltia et al, 2007) (Eisenstein et al, 2013) . Such lack of agreement across the obesity and PET dopamine literature is complex and several factors could be responsible including differences in tracers and research participants. To that end, the radiotracer employed, [ 11 C](+)PHNO, is responsible for at least part of these observed differences and worth further commentary as it has unique properties.
As previously mentioned, . Such a preference might explain why the current study demonstrated higher tracer binding in regions densely populated with D 3 Rs (ie, the SN/VTA and the pallidum) and in the mixed D 2/3 R area of the VST when compared with studies that utilized D 2/3 R antagonist tracers that predominantly estimate D 2 Rs. These distinctions suggest that the D 3 R subtype and the D 2 R subtype may be regulated differently with respect to obesity, a finding also observed in the stimulant-use-disorders literature (Boileau et al, 2012; Lee et al, 2009; Martinez et al, 2004; Matuskey et al, 2014; Payer et al, 2014; Volkow et al, 1990 Volkow et al, , 2001 . Further, the D 3 R has been implicated to be positively associated with behavioral impulsiveness and risky decision making, thus our findings of higher D 3 R availability in OB may be explained by underlying trait impulsivity (Payer et al, 2014) . As such, these data suggest, albeit speculatively, that the D 3 R may be a novel pharmacologic target for the treatment of obesity. In fact, a prior study has demonstrated preliminary evidence that a D 3 R antagonist, when compared with placebo, may attenuate motivational attractiveness to palatable food cues in otherwise healthy OW and OB individuals (Mogg et al, 2012) . However, a follow-up study done by the same group using the same D 3 R antagonist compound failed to show any evidence of changes in neural activation in response to food images on fMRI (Dodds et al, 2012) , thus demonstrating the need for clarity in further studies involving D 3 R antagonist compounds in obesity.
In addition to providing an estimate of D 3 R sites, D 2/3 R alterations in obesity EC Gaiser et al reliably measured in vivo (Seeman, 2012; Skinbjerg et al, 2012) , in theory, only agonist tracers like [ 11 C](+)PHNO would prefer these sites as D 2/3 R antagonist tracers typically bind with equal preference to both high-and low-affinity forms of the D 2/3 R. Therefore, it is possible that these differential binding characteristics could also help explain our VST findings such that the regulation of 'active' highaffinity forms vs 'inactive' low-affinity forms of the D 2/3 R may be altered in obesity. Our finding in the VST is also consistent with the previous [ 11 C](+)PHNO work in non-OB individuals (Caravaggio et al, 2013) and preclinical research that posits the nucleus accumbens, a central component of the VST, plays a key role in the formation/development of the OB phenotype (Davis et al, 2008; Geiger et al, 2009; Hryhorczuk et al, 2016; Rada et al, 2010; Valenza et al, 2015) . This regional specificity, along with tracer properties, may help explain why differences were not found in the dorsal striatum. Evidence does exist that obesity may be mediated by the dorsal striatum through work with preclinical research (Huang et al, 2006) , functional connectivity (ContrerasRodriguez et al, 2015) , and other PET studies done in humans utilizing antagonist tracers (Haltia et al, 2007; Wang et al, 2001) . However, our lack of findings here are not surprising considering [
11 C](+)PHNO has only recently been found to be significantly different in the dorsal striatum of humans with any addiction-like phenotype (Worhunsky et al, 2016) , suggesting decreased sensitivity in this region.
Another potential explanation for dissimilarities between this study and other studies that employed antagonist tracers may be due to endogenous dopamine competition. Without utilizing a pharmacologic intervention such as the tyrosine-hydroxylase inhibitor α-methly-para-tyrosine (AMPT) to deplete tonic dopamine (Abi-Dargham et al, 2000; Caravaggio et al, 2014; Laruelle et al, 1997; Martinez et al, 2009) , our outcome measure, BP ND , reflects tracer bound to receptors not currently occupied by the endogenous neurotransmitter (ie, dopamine) and therefore measures receptor availability (Innis et al, 2007) . [ 11 C](+)PHNO has been shown to be substantially more sensitive to endogenous dopamine competition (ie, increased tracer displacement resulting in lower BP ND ) compared with the antagonist tracers used in prior studies (Cropley et al, 2008; Gallezot et al, 2014a; Ginovart et al, 2006; Moerlein et al, 1997; Shotbolt et al, 2012; Willeit et al, 2008) ; thus, our receptor availability findings could also be due to OB individuals exhibiting lower levels of tonic dopamine. In fact, this concept is consistent with prior reports that have shown dietinduced OB and OB-prone rats exhibited lower levels of tonic dopamine or less dopaminergic-mediated behaviors (ie, conditioned place preference or amphetamine-induced locomotor activity) compared with standard chow fed or OB-resistant controls (Geiger et al, 2009; Hryhorczuk et al, 2016; Rada et al, 2010) .
There are several potential limitations of the current study worth discussing. First, this was a retrospective study, and we did not collect information such as percent adiposity, eating and exercising behavior questionnaires, impulsivity measures, and nutritional intake that would be potentially useful to relate to our PET measures. Future prospective studies may include collecting those measures as well as investigating exercise interventions to examine D 2/3 R transformations as BMI decreases. In fact, one study using [
18 F]fallypride has recently demonstrated that exercise intervention for 8 weeks, compared with psychoeducation, normalized lower striatal D 2/3 Rs in humans with methamphetamine-use disorder (Robertson et al, 2015) . Second, although research participants were gender-and age-matched in the primary between-group comparisons, the cohort for the secondary correlational analyses was heavily dominated by males (33 males vs 9 females); thus, further correlational analyses confirming our findings are warranted in a gender-balanced cohort. Lastly, as previously mentioned, BP ND only reflects PET tracer binding to available receptors and since [ 11 C](+) PHNO is susceptible to endogenous dopamine fluctuations, it is not possible to reconcile whether our findings in OB individuals are driven by an upregulation of D 2/3 Rs or accounted for by lower levels of endogenous dopamine. Future studies employing an AMPT tonic dopamine depletion paradigm may be in order to resolve the underlying effect obesity is having on brain neurochemistry.
In summary, this study, to the best of our knowledge, is the first to examine both striatal and extrastriatal D 2/3 R availability differences between otherwise healthy OB and age-and gender-matched NW individuals utilizing the D 3 -preferring D 2/3 R agonist tracer [ 11 C](+)PHNO. Our data suggest that D 2/3 Rs are higher in OB compared with NW individuals in regions densely populated with D 3 Rs, thus implicating the D 3 R as a potential pharmacologic target for the treatment of obesity. These data also implicate the same nigrostriatal pathway alterations in obesity that have been previously observed with [ 11 C](+)PHNO in cocaine (Matuskey et al, 2014; Payer et al, 2014) , methamphetamine (Boileau et al, 2012) , and alcohol (Erritzoe et al, 2014) abusers, indicating excessive food consumption might alter reward pathways in similar ways as do substances of abuse. The direct role of the D 3 R in addiction is not currently clear . A full discussion is beyond the scope of the current work because of the dynamic interactions of D 3 Rs that include dopamine autoreceptor properties and heterodimers that have diverse direct and indirect effects on GABA, adenosine, and glutamate systems (Casado-Anguera et al, 2016; Fiorentini et al, 2015; Leggio et al, 2015; Sokoloff et al, 2013) . That being stated, one speculative mechanism to explain these phenomena could be that initial responses to ingestion of an addictive substance (ie, drug of abuse or highfat palatable food) causes increases of dopamine which leads to a desensitization of postsynaptic striatal D 2 Rs and a compensatory presynaptic D 3 R upregulation in the SN/VTA on either autoreceptors or postsynaptic GABA neurons, both of which have negative control on dopamine neurons (Sokoloff et al, 2013) .
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